PTC Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PTC Therapeutics, Inc. (PTCT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $41.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-19
- PTC Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $41.10M, a 72.69% increase from fiscal 2024.
- PTC Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $23.80M, a 85.27% decline from fiscal 2023.
- PTC Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $161.60M, a 10.23% increase from fiscal 2022.
- PTC Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $146.60M, a 0.41% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $41.10M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $23.80M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $161.60M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $146.60M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $146.00M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $112.50M 10-K · filed 2022-02-22 | |
| 2019-12-31 | $86.70M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $2.80M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $5.40M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $43.40M 10-K · filed 2018-03-06 | -$43.40M 10-K · filed 2017-03-16 |
| 2015-12-31 | $16.30M 10-K · filed 2017-03-16 | -$16.30M 10-K · filed 2016-02-29 |
| 2014-12-31 | -$9.20M 10-K · filed 2016-02-29 | |
| 2013-12-31 | -$25.60M 10-K · filed 2015-03-02 | |
| 2012-12-31 | -$9.40M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |